- $621.36m
- $603.55m
- $116.59m
Catalyst Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Catalyst Biosciences Posts Quarterly Loss Per Share $0.65
Brief: Singer Julian D Says On March 15,Delivered Letter To Catalyst Biosciences Inc Demanding Right To Inspect Certain Books, Records, Documents
Brief: Catalyst Biosciences Regains Rights To CB 2782-Peg For Treatment Of Dry AMD
Brief: Catalyst Biosciences Says Julian Singer Delivered Notice About Nomination For Election To Co's Board
Catalyst Biosciences Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: Catalyst Biosciences Inc- On Feb 16, Co Received Notice From Nasdaq That Co Is Not In Compliance With Minimum Bid Price Requirement
Brief: Catalyst Biosciences Engages Perella Weinberg Partners To Assist The Company In Exploring Strategic Alternatives
Brief: Julian Singer Says On Jan 26, 2022, JDS1 LLC Delivered Letter To Catalyst Biosciences’S Board
Brief: Catalyst Biosciences Receives Rare Pediatric Disease Designation For CFI Deficiency Treatment
Catalyst Biosciences Inc reports results for the quarter ended in September - Earnings Summary
U.S. RESEARCH ROUNDUP-Chargepoint Holdings, P10, Vector Group
Catalyst Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview
Catalyst Bio slumps on discontinuing development of drug with 'fast track' tag
Brief: Catalyst Biosciences Q3 Loss Per Share $0.80
Catalyst Biosciences Inc expected to post a loss of 66 cents a share - Earnings Preview
Brief: Catalyst Biosciences May Offer And Sell Shares Of Up To $50 Million
Brief: Catalyst Biosciences Announces Chief Financial Officer Transition
Brief: FDA Grants Catalyst Biosciences Orphan Drug Designation For Marzaa For The Treatment Of Factor VII Deficiency